NO984093L - FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider - Google Patents

FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider

Info

Publication number
NO984093L
NO984093L NO984093A NO984093A NO984093L NO 984093 L NO984093 L NO 984093L NO 984093 A NO984093 A NO 984093A NO 984093 A NO984093 A NO 984093A NO 984093 L NO984093 L NO 984093L
Authority
NO
Norway
Prior art keywords
prosaposin
neuropathic pain
methods
derived peptides
relieving neuropathic
Prior art date
Application number
NO984093A
Other languages
English (en)
Norwegian (no)
Other versions
NO984093D0 (no
Inventor
John S O'brien
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO984093D0 publication Critical patent/NO984093D0/no
Publication of NO984093L publication Critical patent/NO984093L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO984093A 1996-03-05 1998-09-04 FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider NO984093L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides
PCT/US1997/004143 WO1997032895A1 (en) 1996-03-05 1997-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides

Publications (2)

Publication Number Publication Date
NO984093D0 NO984093D0 (no) 1998-09-04
NO984093L true NO984093L (no) 1998-11-04

Family

ID=24448513

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984093A NO984093L (no) 1996-03-05 1998-09-04 FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposinavledede peptider

Country Status (16)

Country Link
US (2) US6271196B1 (cg-RX-API-DMAC7.html)
EP (1) EP0929569B1 (cg-RX-API-DMAC7.html)
JP (1) JP4138006B2 (cg-RX-API-DMAC7.html)
KR (1) KR100507715B1 (cg-RX-API-DMAC7.html)
AT (1) ATE340187T1 (cg-RX-API-DMAC7.html)
AU (1) AU734566B2 (cg-RX-API-DMAC7.html)
CA (1) CA2248139C (cg-RX-API-DMAC7.html)
CZ (1) CZ297384B6 (cg-RX-API-DMAC7.html)
DE (1) DE69736712T2 (cg-RX-API-DMAC7.html)
IL (1) IL126082A0 (cg-RX-API-DMAC7.html)
NO (1) NO984093L (cg-RX-API-DMAC7.html)
NZ (1) NZ331757A (cg-RX-API-DMAC7.html)
PL (1) PL187917B1 (cg-RX-API-DMAC7.html)
RU (2) RU2266129C2 (cg-RX-API-DMAC7.html)
SK (1) SK122898A3 (cg-RX-API-DMAC7.html)
WO (1) WO1997032895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
CA2282827A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
JP2001524944A (ja) * 1997-03-05 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 神経障害性疼痛の緩和方法
CA2284105A1 (en) * 1997-03-24 1998-10-01 John S. O'brien Synthetic saposin c-derived neurotrophic peptides
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
EP1011709A4 (en) * 1997-09-09 2003-06-18 Univ California INHIBITION OF APOPTOSIS USING PROSAPOSIN RECEPTOR AGONISTS
CA2341810A1 (en) * 1998-08-28 2000-03-09 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
JP2002544120A (ja) * 1999-03-30 2002-12-24 ミエロスコーポレーション 逆・反転化プロサポシン由来ポリペプチドおよびその使用
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
JP4786843B2 (ja) * 1999-06-16 2011-10-05 マイアロス コーポレイション インターロイキン−６から誘導されるレトロ−インベルソペプチド
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
CA2376394A1 (en) * 1999-06-16 2000-12-21 David E. Wright Retro-inverso peptides derived from interleukin-3
JP2003502341A (ja) * 1999-06-16 2003-01-21 マイアロス コーポレイション 白血病阻害因子に由来するレトロ−インベルソなペプチド
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
EP1418932A4 (en) * 2001-07-18 2006-03-15 Univ Texas ANTIANGIOGENIC CONDITION IN MICE AND PEOPLE WITH RETINAL PHOTOREEPEPTOR DEGENERATION
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US20060275274A1 (en) * 2003-03-26 2006-12-07 Daria Onichtchouk Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
BRPI0409523A (pt) * 2003-03-28 2006-04-18 Acadia Pharm Inc método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
RU2317829C2 (ru) * 2005-10-05 2008-02-27 Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения мононевропатий верхних конечностей
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
RU2345786C2 (ru) * 2007-02-27 2009-02-10 Андрей Евгеньевич Кульчиков Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
CN104689298A (zh) 2008-01-22 2015-06-10 阿拉伊姆药品公司 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
US9327012B2 (en) * 2011-02-23 2016-05-03 Sapporo Medical University Composition for treating, improving, or preventing pain
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
MX2020009829A (es) 2018-03-23 2021-01-08 Bexion Pharmaceuticals Inc Composiciones farmaceuticas de saposina c y metodos para tratar el cancer.
RU2020131598A (ru) 2018-03-29 2022-04-29 Лэйтерал Ип Пти Лтд Циклические пептиды и их применение
MX2023008177A (es) * 2021-01-09 2023-08-30 Bexion Pharmaceuticals Inc Métodos para reducir la neuropatía y síntomas neuropáticos y para el tratamiento contra el cáncer.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108459T1 (de) 1986-04-22 1994-07-15 Salk Inst For Biological Studi Antagonisten des fibroblasten-wachstumsfaktors.
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
RU2007417C1 (ru) * 1991-06-21 1994-02-15 Российский государственный медицинский университет Способ получения плацентарного протеина
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995013823A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
CA2282827A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
CA2284105A1 (en) * 1997-03-24 1998-10-01 John S. O'brien Synthetic saposin c-derived neurotrophic peptides

Also Published As

Publication number Publication date
US6268347B1 (en) 2001-07-31
AU734566B2 (en) 2001-06-14
DE69736712T2 (de) 2007-09-13
EP0929569A4 (en) 2000-08-23
SK122898A3 (en) 2000-02-14
DE69736712D1 (de) 2006-11-02
WO1997032895A1 (en) 1997-09-12
CA2248139A1 (en) 1997-09-12
NO984093D0 (no) 1998-09-04
RU2223969C2 (ru) 2004-02-20
EP0929569B1 (en) 2006-09-20
RU2003131695A (ru) 2005-04-10
KR100507715B1 (ko) 2006-05-26
AU2328697A (en) 1997-09-22
EP0929569A1 (en) 1999-07-21
JP2000506853A (ja) 2000-06-06
IL126082A0 (en) 1999-05-09
JP4138006B2 (ja) 2008-08-20
KR19990087686A (ko) 1999-12-27
US6271196B1 (en) 2001-08-07
NZ331757A (en) 1999-10-28
CZ297384B6 (cs) 2006-11-15
CA2248139C (en) 2004-05-18
RU2266129C2 (ru) 2005-12-20
PL187917B1 (pl) 2004-11-30
CZ283998A3 (cs) 1999-05-12
PL328701A1 (en) 1999-02-15
ATE340187T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
NO984093D0 (no) FremgangsmÕter for lindring av neuropatisk smerte ved bruk av prosaposin-abledete peptider
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
AU9021298A (en) Agmatine as a treatment for neuropathic pain
EA200000239A1 (ru) Стимуляторы секреции гормона роста
EP0813544A4 (cg-RX-API-DMAC7.html)
IL123001A0 (en) Analgesic from snake venom
EA199800866A1 (ru) Способ снятия боли
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
EA199800535A1 (ru) Способ лечения боли
EA199800819A1 (ru) Способ лечения биполярного расстройства
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EP1007050A4 (en) METHOD FOR THE TREATMENT OF DRUG ADDICTION
AU5434899A (en) Cancer treatment
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
NO984190L (no) FremgangsmÕte for behandling av insomnia
NO985325L (no) Anvendelse av substituert azaspiran ved behandling av astma
NO965029D0 (no) Cellulære faktorer som regulerer ekspresjon av gener som koder for proteiner involvert i kolesterolhomeostase
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці
UA36341A (uk) Спосіб лікування запальних процесів навколозубних тканин
UA8280A (uk) Спосіб лікування псоріазу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application